It has been well established that Wnt and MAPK pathways account for CRC progression and metastases [13, 25, 27], and the presence of APC, KRAS, BRAF, PIK3CA, SMAD4 and TP53 mutations closely relates to treatment decision and prognosis. This evidence concerns the gene SMAD4 and colorectal carcinoma.